Fennec Pharmaceuticals Inc.
FENC
$6.68
$0.142.14%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.55% | 29.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.55% | 29.11% | |||
| Cost of Revenue | 167.27% | -31.75% | |||
| Gross Profit | 1.79% | 35.89% | |||
| SG&A Expenses | 21.61% | 5.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.09% | 2.16% | |||
| Operating Income | -1,251.32% | 93.08% | |||
| Income Before Tax | -633.70% | 79.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -650.31% | 79.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -650.31% | 79.76% | |||
| EBIT | -1,251.32% | 93.08% | |||
| EBITDA | -1,450.92% | 93.98% | |||
| EPS Basic | -570.74% | 79.89% | |||
| Normalized Basic EPS | -272.73% | 79.92% | |||
| EPS Diluted | -570.74% | 79.89% | |||
| Normalized Diluted EPS | -272.73% | 79.92% | |||
| Average Basic Shares Outstanding | 11.78% | 0.81% | |||
| Average Diluted Shares Outstanding | 11.78% | 0.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||